Knott David M Jr Boosts Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Knott David M Jr raised its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 875.0% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,000 shares of the company’s stock after acquiring an additional 35,000 shares during the period. Centessa Pharmaceuticals makes up about 0.9% of Knott David M Jr’s investment portfolio, making the stock its 26th largest position. Knott David M Jr’s holdings in Centessa Pharmaceuticals were worth $1,549,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in CNTA. Avoro Capital Advisors LLC boosted its stake in shares of Centessa Pharmaceuticals by 34.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 14,555,555 shares of the company’s stock worth $364,034,000 after purchasing an additional 3,747,475 shares during the period. EcoR1 Capital LLC grew its holdings in Centessa Pharmaceuticals by 466.4% during the 4th quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock valued at $77,906,000 after purchasing an additional 2,565,000 shares during the last quarter. Braidwell LP purchased a new stake in Centessa Pharmaceuticals in the 4th quarter worth about $54,730,000. Maverick Capital Ltd. purchased a new stake in Centessa Pharmaceuticals in the 4th quarter worth about $41,110,000. Finally, Adage Capital Partners GP L.L.C. lifted its stake in Centessa Pharmaceuticals by 20.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock worth $110,415,000 after purchasing an additional 1,449,000 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CNTA. Needham & Company LLC cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Leerink Partners lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and raised their price target for the stock from $36.00 to $40.00 in a research note on Wednesday, April 1st. Stephens cut Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Wolfe Research downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Guggenheim downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $41.33.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock opened at $40.50 on Friday. The company has a market capitalization of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11. The company’s 50-day simple moving average is $40.12 and its two-hundred day simple moving average is $33.64. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $12.74 and a one year high of $40.56. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.